Stocks That Surged Higher Over The Past Week: $ZSAN $ADMS $EXPI

*If You Own ZSAN, ADMS, EXPI Then Click Here to Join Our Community of Traders

The Market Signal was created as a platform to help investors, if you own (NASDAQ:ZSAN), (NASDAQ:ADMS) or (NASDAQ:EXPI) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

(Click the link above or copy, paste and hit enter in your browser for your report)

Zosano Pharma Enters Partnership With EVERSANA For Commercialization of Qtrypta Free-Report/ZSAN

(Click the link above or copy, paste and hit enter in your browser for your report)

Zosano Pharma (NASDAQ:ZSAN) surged 56.00% over the last one week. The company entered a partnership with EVERSANA for the commercialization and distribution of Qtrypta(TM) in the US. The FDA approved an NDA for Qtrypta in March and also awarded a PDUFA goal timeline of October 20, 2002. Once approved Qtrypta will be the only and first microneedle patch indicated for the treatment of acute migraine.

The company reported its Q2 2020 results and it posted a net loss of $7.9 million or $0.14 a share on a diluted and basic basis. In the quarter R&D expenses dropped to $4.9 million compared to $6.6 reported in Q2 2019 which was due to the low clinical study costs following the completion of the Qtrypta study last year. Cash and equivalent for the period ended June 30, were $10.5 million.

Adamas Pharmaceuticals Reports Revenue of $18.8 million in Q2 2020 Free-Report/ADMS

(Click the link above or copy, paste and hit enter in your browser for your report)

Adamas Pharmaceuticals (NASDAQ:ADMS) also surged higher this past week with the stock up 52.42%. The company has announced its Q2 2020 results and offered a corporate update. Adamas attained a huge milestone in the quarter following the FDA acceptance to review its sNDA for GOCOVRI in treating OFF episodes in patients with Parkinson's disease under levodopa therapy. Paid GOCOVRI prescriptions in Q2 20202 were around 8,150 which is a 32 YoY increase.

Revenue in the quarter was $18.8 million with GOCOVRI sales accounting for $18 million and royalty revenue from NAMZARIC net sales being 0.8 million. GOCOVRI sales grew 41% in the quarter relative to Q2 2019's $12.7 million.

VirBELA And eXp Realty Announced The Acquisition Of Showcase IDX Assets Free-Report/EXPI

(Click the link above or copy, paste and hit enter in your browser for your report)

Another stock that surged higher this past week is eXp World Holdings (NASDAQ:EXPI) which was up 46.55%. The parent company of VirBELA and eXp Realty announced the acquisition of Showcase IDX assets. Showcase IDX is a real estate search tech company that assists agents in growing their market presence online. The acquisition will help eXP to strategically focus on the creation of a consumer portal as well as home-search tech innovation. Equally, Showcase will help in driving expansion of the current IDX product and business this creating improvements and value for customers with time.

The company's CEO, Glenn Sanford expressed his appreciation for the team of tech experts brought together by Showcase.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.


comtex tracking


Is there a problem with this press release? Contact the source provider Comtex at

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.